Cautionary

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Blockchain Moon Acquisition Corp. appoints John P. Hopkins and Carl J. Johnson as new Independent Directors

Jacksonville, FL, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Blockchain Moon Acquisition Corp. (“BMAC”)  (Nasdaq: BMAQ) announces that on September 14, 2022, John P. Hopkins and Carl J. Johnson were appointed to the board of directors as new independent board members.  “We are excited to have two extremely experienced board members added to the board as independent directors. Their backgrounds as executive directors, officers, and advisors come at a great benefit to the stockholders of Blockchain Moon Acquisition Corp.,” commented Enzo Villani, Chairman, and CEO of BMAC. Mr. Hopkins has 40 years of experience in accounting, finance